Recent Updates
Recently added Catalysts
TMDX Positive Sentiment Score: 70/100

TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Key Takeaway: TransMedics Group, Inc. has announced that it will report its financial results for the second quarter of 2025 on July 30, 2025. The report will be released after market close, followed by a conference call at 4:30 p.m. ET. TransMedics specializes in organ transplant therapy, utilizing cutting-edge technology to improve organ viability and increase donor organ utilization. Investors will have access to both a live and archived webcast of the conference call on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • TransMedics is transforming organ transplant therapy for patients with end-stage organ failure.
  • The company is recognized as a leader in organ preservation and assessment technologies.
  • A financial results announcement indicates potential growth and stakeholder engagement.

Full Press Release Details

ANDOVER, Mass. , July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025 . The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT .
Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domestic callers or (412) 634-6944 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact: Brian Johnston Laine Morgan 332-895-3222 [email protected]
SOURCE TransMedics Group, Inc.

21 %

Frequently Asked Questions

When will TransMedics release its Q2 2025 financial results?

TransMedics will release its Q2 2025 financial results on July 30, 2025.

How can I join the TransMedics conference call?

Dial (844) 676-6010 for domestic or (412) 634-6944 for international access.

Where can I find the webcast of the conference call?

The live and archived webcast will be available on TransMedics' Investors page.

What does TransMedics specialize in?

TransMedics specializes in portable extracorporeal warm perfusion for donor organs.

Where is TransMedics Group, Inc. headquartered?

TransMedics is headquartered in Andover, Massachusetts.

Last updated: Jul 16, 2025